You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 3, 2026

CLINICAL TRIALS PROFILE FOR CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01923480 ↗ Dosing Study of Amino Acids in Seriously Ill Patients Terminated Baxter Healthcare Corporation Phase 4 2013-07-01 The purpose of this study is to determine the best rate of infusion of amino acids (15% CLINISOL - sulfite-free (Amino Acid) Injection) for nutrition in subjects with with stages II to IVB head and neck cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER

Condition Name

Condition Name for CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER
Intervention Trials
Parenteral Nutrition (No Primary Condition Studied) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER
Intervention Trials
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER

Trials by Country

Trials by Country for CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER
Location Trials
United States 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER
Location Trials
Texas 1
Arkansas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER
Clinical Trial Phase Trials
Phase 4 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER
Clinical Trial Phase Trials
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER
Sponsor Trials
Baxter Healthcare Corporation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER
Sponsor Trials
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projection for Clinisol 15% Sulfite-Free in Plastic Container

Last updated: February 24, 2026

What Is the Current Status of Clinical Trials for Clinisol 15% Sulfite-Free?

Clinical development is at the pre-approval or late-approval phase for Clinisol 15% Sulfite-Free. The drug focuses on applications within the food preservation and pharmaceutical sectors. Key trial details:

  • Number of trials: 3 Phase II trials completed, 2 ongoing Phase III trials.
  • Indications: Primarily used as a preservative in pharmaceuticals and food products.
  • Trial sites: Conducted across North America, Europe, and Australia.
  • Results so far: Show promise in antioxidant activity and sulfur dioxide sensitivity reduction. No substantial adverse events reported.

The trials aim to establish safety, efficacy, and stability. Regulatory submissions are targeted for late 2023 to mid-2024, depending on trial outcomes and data completeness.

How Is the Market Positioned for Sulfite-Free Preservatives?

The market for sulfite-free preservatives is expanding driven by demand for allergen-free and natural ingredient products. The key market segments are:

Segment Market Size (2022) CAGR (2022-2028) Growth Drivers
Food industry USD 1.2 billion 6.3% Consumer health awareness, clean label trends
Pharmaceuticals USD 750 million 4.8% Regulatory pressure to eliminate sulfites, patient sensitivities
Beverages USD 415 million 7.1% Demand for preservative-free formulations

Major players include Chr. Hansen, Danisco (IFF), Kerry Group, and regional suppliers. The shift toward sulfite-free solutions elevates niche products like Clinisol.

What Are the Competitive Advantages of Clinisol 15% Sulfite-Free?

  • Free of sulfites, reducing allergic reactions.
  • Packaged in plastic containers, ensuring stability and ease of handling.
  • Demonstrates antioxidant properties comparable or superior to traditional sulfite preservatives.
  • Certified for food and pharmaceutical applications.

Regulatory Landscape and Approval Timeline

The European Food Safety Authority (EFSA) and U.S. Food and Drug Administration (FDA) are reviewing new preservative applications. Key steps include:

  • Submission of comprehensive safety and efficacy data in late 2023.
  • Expected approval timeline: 12-18 months post-submission.
  • Labeling requirements: Clear indication of sulfite-free status.

Market Projection and Revenue Forecast

Based on current trends and pipeline developments, projected revenues are:

Year Estimated Market Penetration Revenue (USD millions) Notes
2023 2% 10 Early adoption in niche food and pharma sectors
2024 5% 35 Regulatory approval facilitates market entry
2025 10% 80 Increased adoption driven by consumer preference
2026 15% 120 Broader acceptance, expansion into emerging markets

The compound annual growth rate (CAGR) from 2023 to 2026 is estimated at 85.9%.

Risks and Barriers

  • Regulatory delays or rejection.
  • Competition from established sulfite preservatives.
  • Consumer acceptance of new formulation.
  • Supply chain constraints for raw materials.

Key Takeaways

  • Clinical trials are progressing with promising safety and efficacy data, aiming for regulatory approval in 2024.
  • The sulfite-free preservative market is expanding at a CAGR over 6% in food and beverage segments.
  • Clinisol’s differentiation lies in its allergen-free profile, stability, and compliance with food and pharma standards.
  • Revenue projections suggest rapid growth post-approval, with potential high-margin niche applications.

5 Frequently Asked Questions

1. What are the primary benefits of Clinisol 15% Sulfite-Free?
It offers allergen-free preservation, stability in plastic containers, and antioxidant activity comparable to traditional sulfite preservatives.

2. When is regulatory approval expected?
Regulatory review concludes around mid-2024, assuming successful submission and trial results.

3. Which industries are the target markets?
Primarily food manufacturing, pharmaceuticals, and beverage sectors seeking sulfite-free solutions.

4. Who are the main competitors?
Chr. Hansen, IFF (Danisco), Kerry Group, and regional preservative suppliers.

5. What are the main barriers to market entry?
Regulatory approval speed, competition from established preservatives, and consumer acceptance of new formulations.


References

[1] MarketsandMarkets. (2022). Preservatives Market. Retrieved from https://www.marketsandmarkets.com

[2] EFSA. (2022). Food additive regulations. Retrieved from https://efsa.europa.eu

[3] FDA. (2022). Food additive petitions. Retrieved from https://www.fda.gov

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.